PAID CLINICAL TRIAL
- Lasting 5 years
YOU MAY BE ELIGIBLE TO PARTICIPATE IF YOU MEET THE FOLLOWING CRITERIA:
- Are 50 years of age or older
- High Risk of Atherosclerotic Cardiovascular Disease
?>
» Studies » Atherosclerotic Cardiovascular Disease
» Studies » Atherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease
Purpose Of Study
The purpose of this study is being done to learn more about olpasiran (also known as AMG 890) in people with elevated Lp[a], and risk factors for ASCVD and/or evidence of cholesterol plaques in the arteries. If you have elevated Lp(a) levels and risk factors for ASCVD and/or evidence of atherosclerosis, this means you may have a higher risk for new heart or blood
vessel disease events.
The study is being done primarily to:
See if olpasiran reduces the risk of having a cardiovascular event such as heart attack, an urgent procedure to improve blood flow through the coronary (heart) vessel or death due to heart disease. Understand if olpasiran causes any side effects and how well it is tolerated.
View Studies by Location
Chattanooga, TN
Colorado Springs, CO (Temporarily Closed)
Oklahoma City East, OK
Oklahoma City, OK
Tulsa, OK
all Studies
LEARN MORE ABOUT PARTICIPATING IN A CLINICAL TRIAL
Lynn Institute is a leader in introducing new medications to the market through our clinical trials program. Visit our Participation Information page for Frequently Asked Questions, to see current clinical trials listed, and to find out where each trial is being conducted.
Find out More About Our Participation Program
Participation Information